AMSTERDAM · EST. 2026
Onpeps
PEPTIDE DECISION INTELLIGENCE
Subscribe
← PEPTIDE LIBRARY
GROWTH HORMONEGRADE ASTRONG HUMAN EVIDENCE

Tesamorelin

GHRH analog

A stabilised growth-hormone-releasing hormone analog and the only approved GH secretagogue. Approved specifically to reduce excess visceral fat in HIV-associated lipodystrophy.

ALSO KNOWN AS Egrifta
REGULATORY STATUS · FDA-APPROVED

FDA-approved (Egrifta) for HIV-associated lipodystrophy.

§ EVIDENCE BASE
93
PUBLICATIONS
indexed in PubMed
24
REGISTERED TRIALS
listing it as an intervention
14
PHASE 2–4 TRIALS
reached later-stage testing
MECHANISMGHRH analog
CATEGORYGrowth Hormone
EVIDENCE GRADEA — Strong human evidence
STATUSFDA-approved (Egrifta) for HIV-associated lipodystrophy
TYPICAL RECONSTITUTIONReconstitute per label / pharmacy instructions
ROUTESubcutaneous — abdomen
COUNTS RETRIEVED2026-07-23 · re-run the PubMed query
§ DOCUMENTED DOSING
Standard2 mg once daily
Best timingbefore bed, subcutaneous
Cycleongoing, per prescriber

Ranges compiled from published protocols, not a clinical guideline. Convert a dose into syringe units with the dosage calculator.

§ RELATED COMPOUNDS
GROWTH HORMONEC
Ipamorelin
Selective ghrelin receptor agonist (GH secretagogue)
GROWTH HORMONED
CJC-1295
GHRH analog (with or without DAC)
NOT MEDICAL ADVICE

This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.

THE WEEKLY BRIEF

Peptide intelligence, every Monday.

One concise email: the newest research, evidence updates, and quality signals — no hype, no spam.

Onpeps

Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.

EXPLORE
FOLLOW
PEPTIDE INFORMATION YOU CAN VERIFY© 2026 ONPEPS · AMSTERDAM, NETHERLANDS · NOT MEDICAL ADVICE